Eli Lilly gets a licence for oral medicines that Insilico has in early development—for certain unspecified illnesses—and a research-and-development partner that has AI-based tools for finding molecules that could become useful new drugs. Insilico gets $115 million up front and the potential of milestone payments taking the amount up to $2.75 billion as medicines move through development, and potential royalties on eventual sales. (The Logic)
Talking point: Insilico has widespread global operations but Montreal is at the core of its artificial intelligence research and CEO Alex Zhavoronkov is a Latvian-Canadian partly educated at Queen’s University. The company announced a similar development deal with French pharma company Servier in early January, days after going public on the Hong Kong Stock Exchange. Its share price has risen more than 50 per cent this year.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.